PE20020695A1 - Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina - Google Patents
Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosinaInfo
- Publication number
- PE20020695A1 PE20020695A1 PE2001001203A PE2001001203A PE20020695A1 PE 20020695 A1 PE20020695 A1 PE 20020695A1 PE 2001001203 A PE2001001203 A PE 2001001203A PE 2001001203 A PE2001001203 A PE 2001001203A PE 20020695 A1 PE20020695 A1 PE 20020695A1
- Authority
- PE
- Peru
- Prior art keywords
- egf
- ligands
- rtk
- tumors
- treatment
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 5
- 239000003446 ligand Substances 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 2
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMBINACION UTIL PARA INMUNOTERAPIA QUE TIENE EFECTO SOBRE EL CRECIMIENTO O PROLIFERACION DE CELULAS DEPENDIENTE DE LA INTERACCION ENTRE RECEPTORES DE QUINASAS EN RESIDUOS DE TIROSINA (RTK) Y SU LIGANDO QUE COMPRENDE: a)UN ANTICUERPO CONTRA UN RECEPTOR RTK O EGF (FACTOR DE CRECIMIENTO EPIDERMICO), PUDIENDO SER HUMANIZADO COMO hR3 O MONOCLONAL; b)UNA VACUNA CUYO PRINCIPIO ES EL RECEPTOR DE RTK (EGF) QUE INDUCE ANTICUERPOS (HUMANIZADOS) CONTRA DICHO RECEPTOR RTK (EGF) O COMPRENDE: a)UN ANTICUERPO CONTRA LOS LIGANDOS DEL RECEPTOR RTK O EGF TAL COMO FACTOR DE CRECIMIENTO TRANSFORMANTE DE TIPO O (TGFO); b)UNA VACUNA CUYO PRINCIPIO ACTIVO SON LOS LIGANDOS DEL RECEPTOR RTK Y QUE INDUCE ANTICUERPOS CONTRA LOS LIGANDOS; QUE COMPRENDE UN CONJUGADO ENTRE LAS PROTEINAS p64K Y EGF O p64K Y TGF. LA COMBINACION POTENCIA EL BLOQUEO DE LIGANDOS Y RECEPTOR IMPIENDO EL CRECIMIENTO O PROLIFERACION CELULAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20000287A CU22979A1 (es) | 2000-12-08 | 2000-12-08 | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020695A1 true PE20020695A1 (es) | 2002-09-23 |
Family
ID=40261022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001203A PE20020695A1 (es) | 2000-12-08 | 2001-11-29 | Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20020160014A1 (es) |
| EP (2) | EP2005996A3 (es) |
| JP (2) | JP2005519023A (es) |
| KR (1) | KR20030064416A (es) |
| CN (1) | CN1326566C (es) |
| AR (1) | AR031641A1 (es) |
| AT (1) | ATE403438T1 (es) |
| AU (2) | AU2002221521B2 (es) |
| BR (1) | BR0116010A (es) |
| CA (1) | CA2431199C (es) |
| CU (1) | CU22979A1 (es) |
| CY (1) | CY1108474T1 (es) |
| DE (1) | DE60135248D1 (es) |
| DK (1) | DK1350521T3 (es) |
| EA (1) | EA007381B1 (es) |
| ES (1) | ES2311036T3 (es) |
| HK (1) | HK1073244A1 (es) |
| MX (1) | MXPA03005030A (es) |
| MY (1) | MY138833A (es) |
| NZ (1) | NZ526284A (es) |
| PE (1) | PE20020695A1 (es) |
| PT (1) | PT1350521E (es) |
| SI (1) | SI1350521T1 (es) |
| UY (1) | UY27058A1 (es) |
| WO (1) | WO2002045747A1 (es) |
| ZA (1) | ZA200304415B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
| CU23297A1 (es) * | 2004-11-16 | 2008-07-24 | Ct De Inmunologa A Molecular | Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer |
| US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
| CA2665528C (en) | 2006-10-12 | 2018-01-23 | The University Of Tokyo | Diagnosis and treatment of cancer using anti-ereg antibody |
| CU23652A1 (es) * | 2007-06-29 | 2011-05-27 | Centro Inmunologia Molecular | Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención |
| JP5420568B2 (ja) | 2008-01-17 | 2014-02-19 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 改良された抗ＴｒｋＢ抗体 |
| EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
| TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| CA3053239A1 (en) * | 2017-02-17 | 2018-08-23 | George Todaro | Use of tgf alpha for the treatment of diseases and disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| JPH01221326A (ja) * | 1988-02-29 | 1989-09-04 | Toyo Jozo Co Ltd | 悪性腫瘍細胞障害剤 |
| US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
| EP0586002B1 (en) | 1992-08-18 | 2000-01-19 | CENTRO de IMMUNOLOGIA MOLECULAR | Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them |
| CA2261433A1 (en) | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| EP0657175B1 (en) * | 1993-12-09 | 2005-03-02 | Centro de Inmunologia Molecular | Vaccine comprising human autologous epidermal growth factor and use thereof |
| CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| BR9811264A (pt) * | 1997-05-12 | 2000-07-18 | Aphton Corp | Composições imunogênicas ao receptor de gastrina/cck-b e métodos para o tratamento de tumores |
| US20030219380A1 (en) * | 1997-11-07 | 2003-11-27 | Annie Fong | Method of determining an efficacious dose of a drug |
| JP2002514573A (ja) * | 1998-05-08 | 2002-05-21 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 能動的なワクチン接種のための組成物および方法 |
| JP2002515511A (ja) * | 1998-05-15 | 2002-05-28 | イムクローン システムズ インコーポレイティド | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 |
| US6498181B1 (en) * | 1999-01-06 | 2002-12-24 | Maxim Pharmaceuticals | Synergistic tumorcidal response induced by histamine |
| EP1303533A2 (en) * | 2000-05-05 | 2003-04-23 | Aphton Corporation | Chimeric peptide immunogens, their preparation and use |
| CU23077A1 (es) * | 2000-12-06 | 2005-08-17 | Centro Inmunologia Molecular | Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas |
-
2000
- 2000-12-08 CU CU20000287A patent/CU22979A1/es unknown
-
2001
- 2001-11-29 PE PE2001001203A patent/PE20020695A1/es not_active Application Discontinuation
- 2001-12-05 MY MYPI20015556A patent/MY138833A/en unknown
- 2001-12-06 AU AU2002221521A patent/AU2002221521B2/en not_active Ceased
- 2001-12-06 EP EP08161862A patent/EP2005996A3/en not_active Withdrawn
- 2001-12-06 AU AU2152102A patent/AU2152102A/xx active Pending
- 2001-12-06 CN CNB018216854A patent/CN1326566C/zh not_active Expired - Fee Related
- 2001-12-06 JP JP2002547530A patent/JP2005519023A/ja active Pending
- 2001-12-06 CA CA2431199A patent/CA2431199C/en not_active Expired - Fee Related
- 2001-12-06 DE DE60135248T patent/DE60135248D1/de not_active Expired - Lifetime
- 2001-12-06 DK DK01999388T patent/DK1350521T3/da active
- 2001-12-06 PT PT01999388T patent/PT1350521E/pt unknown
- 2001-12-06 UY UY27058A patent/UY27058A1/es unknown
- 2001-12-06 SI SI200130873T patent/SI1350521T1/sl unknown
- 2001-12-06 ES ES01999388T patent/ES2311036T3/es not_active Expired - Lifetime
- 2001-12-06 AT AT01999388T patent/ATE403438T1/de active
- 2001-12-06 KR KR10-2003-7007630A patent/KR20030064416A/ko active Search and Examination
- 2001-12-06 WO PCT/CU2001/000012 patent/WO2002045747A1/es active IP Right Grant
- 2001-12-06 EP EP01999388A patent/EP1350521B1/en not_active Expired - Lifetime
- 2001-12-06 BR BR0116010-9A patent/BR0116010A/pt not_active IP Right Cessation
- 2001-12-06 NZ NZ526284A patent/NZ526284A/en not_active IP Right Cessation
- 2001-12-06 MX MXPA03005030A patent/MXPA03005030A/es active IP Right Grant
- 2001-12-06 EA EA200300646A patent/EA007381B1/ru not_active IP Right Cessation
- 2001-12-07 AR ARP010105686A patent/AR031641A1/es not_active Application Discontinuation
- 2001-12-07 US US10/005,341 patent/US20020160014A1/en not_active Abandoned
-
2003
- 2003-06-05 ZA ZA200304415A patent/ZA200304415B/en unknown
-
2005
- 2005-07-11 HK HK05105840A patent/HK1073244A1/xx not_active IP Right Cessation
-
2006
- 2006-04-20 US US11/407,103 patent/US7744871B2/en not_active Expired - Lifetime
-
2008
- 2008-11-03 CY CY20081101242T patent/CY1108474T1/el unknown
-
2010
- 2010-03-23 JP JP2010066088A patent/JP2010150286A/ja not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020695A1 (es) | Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina | |
| GT200900051A (es) | Proteinas de union a interleuquina-13 | |
| MX2019012811A (es) | Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion. | |
| BR112018007296A2 (pt) | conjugados de anticorpo compreendendo agonista de receptor tipo toll | |
| AR073538A1 (es) | Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf) | |
| CO5700152A1 (es) | Nuevos anticuerpos anti-igf-ir y sus usos | |
| PE20181399A1 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica | |
| CR8231A (es) | Anticuerpos rg1 y uso de los mismos | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| EA201600190A1 (ru) | Анти-prlr антитела и их применение | |
| PE20110008A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
| DE60334364D1 (de) | Behandlungsverfahren unter verwendung von anti-cd22-antikörpern | |
| TW200616662A (en) | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates | |
| AR064464A1 (es) | Anticuerpos anti - receptor del factor de crecimiento insulinico | |
| CR20130154A (es) | Proteínas de la unión a il-12/p40 (divisional exp. 9599) | |
| CY1106594T1 (el) | Αντισωματα εναντι ανθρωπινης il-12 | |
| CR20120312A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| AR044927A1 (es) | Metodos y composiciones para tratar la artritis reumatoidea | |
| AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
| ECSP10010653A (es) | Anticuerpos anti-il-17a/il-17f de reactividad cruzada y métodos de uso de los mismos | |
| NZ616254A (en) | Complexes of il-15 and il-15ralpha and uses thereof | |
| DE602005025531D1 (de) | Saccharid-konjugatvakzine | |
| CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
| ECSP088733A (es) | Anticuerpos anti-5t4 y usos de los mismos | |
| PE20130324A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |